Whole‐brain mapping of amylin‐induced neuronal activity in receptor activity–modifying protein 1/3 knockout mice [PDF]
The pancreatic hormone amylin plays a central role in regulating energy homeostasis and glycemic control by stimulating satiation and reducing food reward, making amylin receptor agonists attractive for the treatment of metabolic diseases.
Hecksher‐Sørensen, Jacob; https://orcid.org/ +9 more
core +1 more source
Global Landscape and Thematic Evolution of Selective GLP-1 Receptor Agonists and GLP-1-Based Multi-Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis. [PDF]
Bibliometric analysis of 3736 publications (2004–2025) reveals rapid growth in GLP‐1–based T2DM research. The US leads, with Novo Nordisk and Eli Lilly as top contributors. Thematic shifts from glycemic control toward cardiovascular‐kidney‐metabolic outcomes and real‐world evidence, driven by landmark trials like LEADER and REWIND.
Wang Y +6 more
europepmc +2 more sources
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. [PDF]
Background Long‐acting amylin‐based therapies (ABTs) are emerging anti‐obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and
Kamrul-Hasan ABM +5 more
europepmc +2 more sources
Functional study of amylin and regulation of amylin receptor [PDF]
Amylin, a 37 amino acid peptide secreted from pancreatic beta cells upon stimulation by meal/glucose, belongs to the family of the calcitonin or calcitonin gene-related peptide (CGRP) and shares up to 50% homology with CGRP, which is a well-documented ...
Huang, Xiaofang
core +1 more source
Diabesity: an old term, a modern challenge - multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes. [PDF]
Type 2 diabetes mellitus (T2DM) and obesity are closely interconnected but heterogeneous conditions in which treatment response, safety, body weight, glycemic control, and long-term clinical outcomes vary substantially between individuals. This narrative
Hoffmann K +18 more
europepmc +2 more sources
AMYLIN AND AMYLIN ANALOGS – FUTURE THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY [PDF]
Amylin is a peptide hormone co-synthesized with insulin in pancreatic beta cells at a ratio of 1:100. Notably, amylin has a pronounced tendency to form toxic amyloid fibrils, a characteristic relevant to its pathological role.
Nikolinka Koleva +2 more
doaj +1 more source
An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side
There is a substantial need for new pharmacological treatments of addiction, and appetite-regulatory peptides are implied as possible candidates. Appetite regulation is complex and involves anorexigenic hormones such as glucagon-like peptide-1 (GLP-1 ...
Olesya T. Shevchouk +2 more
doaj +1 more source
Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity. [PDF]
Amylin is a pancreatic peptide hormone that regulates blood glucose levels and appetite. This review outlines the physiological role of amylin and highlights recent clinical studies exploring its therapeutic potential in diabetes and obesity.
Chung CW, Kim J.
europepmc +2 more sources
Objective: Dual amylin and calcitonin receptor agonists (DACRAs) are novel therapeutic agents that not only improve insulin sensitivity but also work as an adjunct to established T2DM therapies.
K.V. Andreassen +5 more
doaj +1 more source
Highly potent, selective acylguanidine-type histamine H2 receptor agonists: synthesis and structure-activity relationships [PDF]
Potent and selective histamine H2 receptor (H2R) agonists are valuable pharmacological tools and might be of therapeutic value as drugs, for example in the treatment of severe congestive heart failure.
Kraus, Anja
core +1 more source

